Traws Pharma (TRAW) Expected to Post Earnings on Thursday

Traws Pharma (NASDAQ:TRAW) will likely be releasing its Q3 2026 resultson Thursday, November 12th. Analysts expect Traws Pharma to announce earnings of ($0.21) per share and revenue of $2.71 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Friday, August 14th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. On average, analysts expect Traws Pharma to post ($1.20) EPS for the current fiscal year and ($1.24) EPS for the next fiscal year.

Traws Pharma Stock Up 8.2%

Shares of Traws Pharma stock opened at $0.24 on Tuesday. Traws Pharma has a 52 week low of $0.22 and a 52 week high of $3.23. The business’s fifty day simple moving average is $0.45 and its 200-day simple moving average is $1.12.

Analyst Ratings Changes

A number of brokerages recently issued reports on TRAW. Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Traws Pharma in a research report on Tuesday, August 18th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $1.00.

Traws Pharma Company Profile

Traws Pharma, Inc is a clinical-stage biotechnology company focused on developing antiviral medicines for respiratory viral infections, including influenza and COVID-19. The company’s approach includes developing therapies designed to act against viral replication and host-cell pathways involved in disease progression.

Traws Pharma’s pipeline includes zapnometinib, an investigational oral host-directed antiviral designed to inhibit the MEK signaling pathway, which may support treatment across multiple strains of influenza and coronaviruses.